CA1180009A - Platinum complexes - Google Patents
Platinum complexesInfo
- Publication number
- CA1180009A CA1180009A CA000394370A CA394370A CA1180009A CA 1180009 A CA1180009 A CA 1180009A CA 000394370 A CA000394370 A CA 000394370A CA 394370 A CA394370 A CA 394370A CA 1180009 A CA1180009 A CA 1180009A
- Authority
- CA
- Canada
- Prior art keywords
- cis
- diammineplatinum
- oco
- preparation
- hoco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003057 platinum Chemical class 0.000 title claims abstract description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims abstract description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- UOHYCYGTFKYJSP-UHFFFAOYSA-N azane;platinum(2+);dinitrate Chemical compound N.N.[Pt+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O UOHYCYGTFKYJSP-UHFFFAOYSA-N 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 19
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract description 5
- 229960004316 cisplatin Drugs 0.000 abstract description 5
- 206010029155 Nephropathy toxic Diseases 0.000 abstract description 2
- 230000007694 nephrotoxicity Effects 0.000 abstract description 2
- 231100000417 nephrotoxicity Toxicity 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 27
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- -1 alkali metal salts Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001076939 Artines Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- RGHNJXZEOKUKBD-QTBDOELSSA-N L-gulonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-QTBDOELSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001077660 Molo Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100238304 Mus musculus Morc1 gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- FDXOVWIMYQPHRO-HWZSTGBWSA-M sodium;(2s,3s,4s,5r)-3,4,5,6-tetrahydroxyoxane-2-carboxylate;hydrate Chemical compound O.[Na+].OC1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O FDXOVWIMYQPHRO-HWZSTGBWSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56009463A JPS57123198A (en) | 1981-01-23 | 1981-01-23 | Novel platinum complex |
| JP9463/1981 | 1981-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1180009A true CA1180009A (en) | 1984-12-27 |
Family
ID=11720966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000394370A Expired CA1180009A (en) | 1981-01-23 | 1982-01-18 | Platinum complexes |
Country Status (7)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5921697A (ja) * | 1982-06-24 | 1984-02-03 | Yoshinori Kitani | 新規な白金錯体 |
| JPS59222498A (ja) * | 1983-06-01 | 1984-12-14 | Shionogi & Co Ltd | 新規グリコ−ル酸系白金錯体および抗悪性腫瘍剤 |
| US4562275A (en) * | 1984-03-23 | 1985-12-31 | Bristol-Myers Co. | Antitumor platinum complexes |
| JPS617283A (ja) * | 1984-06-20 | 1986-01-13 | Shionogi & Co Ltd | 新規白金錯体および抗悪性腫瘍剤 |
| IL76889A0 (en) * | 1984-11-02 | 1986-02-28 | Johnson Matthey Plc | Solubilised platinum compound,method for the production thereof and pharmaceutical compositions containing the same |
| NZ214504A (en) * | 1984-12-17 | 1988-07-28 | American Cyanamid Co | Platinum/saccharide complexes and pharmaceutical compositions |
| JPS6296A (ja) * | 1985-03-06 | 1987-01-06 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金（２）錯体 |
| JPH0665648B2 (ja) * | 1985-09-25 | 1994-08-24 | 塩野義製薬株式会社 | 白金系抗癌物質の安定な凍結真空乾燥製剤 |
| KR880701103A (ko) * | 1986-05-21 | 1988-07-25 | 나까무라 히사오 | 신규 복합체, 그의 제조방법 및 그 복합체의 의약용도 |
| US5011959A (en) * | 1986-11-17 | 1991-04-30 | The Board Of Regents, The University Of Texas System | 1,2-diaminocyclohexane-platinum complexes with antitumor activity |
| KR900003457B1 (ko) * | 1986-12-18 | 1990-05-19 | 시오노기세이야꾸 가부시끼가이샤 | 암민-지환식아민-백금 착화합물 및 항종양제 |
| WO1989000574A1 (en) * | 1987-07-17 | 1989-01-26 | Georgetown University | Platinum pharmaceuticals |
| US4895935A (en) * | 1987-07-17 | 1990-01-23 | Georgetown University | Platinum pharmaceuticals |
| US4956459A (en) * | 1987-07-17 | 1990-09-11 | Georgetown University | Platinum compounds suitable for use as pharmaceuticals |
| US4895936A (en) * | 1987-07-17 | 1990-01-23 | Georgetown University | Platinum pharmaceuticals |
| JPH01294683A (ja) * | 1988-02-04 | 1989-11-28 | Kanebo Ltd | 新規白金錯体および該化合物を有効成分とする抗腫瘍剤並びに該化合物製造用中間体 |
| WO1990003402A1 (en) * | 1988-09-27 | 1990-04-05 | Kuraray Co., Ltd. | Novel composite, process for its preparation and medicinal use thereof |
| US5393909A (en) * | 1988-11-22 | 1995-02-28 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US4946954A (en) * | 1989-01-17 | 1990-08-07 | Georgetown University | Platinum pharmaceutical agents |
| US5130450A (en) * | 1990-04-25 | 1992-07-14 | Nippon Kayaku Kabushiki Kaisha | Platinum complexes |
| AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| JP5364381B2 (ja) * | 2006-12-08 | 2013-12-11 | 片山化学工業株式会社 | アンミン白金錯体を高濃度で内包するリポソームおよびその製造方法 |
| CN100500682C (zh) * | 2007-02-14 | 2009-06-17 | 江苏奥赛康药业有限公司 | 一种奈达铂的提纯方法 |
| CN101402655B (zh) * | 2008-11-07 | 2011-06-15 | 江苏奥赛康药业有限公司 | 一种米铂的制备方法 |
| CN102417522B (zh) * | 2011-10-20 | 2014-11-26 | 南京工业大学 | 一种奈达铂的制备方法 |
| CN105399777A (zh) * | 2015-11-23 | 2016-03-16 | 南京先声东元制药有限公司 | 一种奈达铂类似物及其制备方法 |
| CN105622673B (zh) * | 2016-01-25 | 2018-11-06 | 南开大学 | 具有抗癌活性的糖基化四价铂类化合物、制备方法及应用 |
| CN112225757B (zh) * | 2020-09-17 | 2023-07-21 | 昆明贵研药业有限公司 | 一种洛铂三水合物的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH605550A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-06-08 | 1978-09-29 | Research Corp | |
| US4115418A (en) * | 1976-09-02 | 1978-09-19 | Government Of The United States Of America | 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity |
| JPS5829957B2 (ja) * | 1977-09-12 | 1983-06-25 | 喜徳 喜谷 | 新規な白金錯体 |
| SE447902B (sv) * | 1977-10-19 | 1986-12-22 | Johnson Matthey Co Ltd | Cis-koordinationsforening av platina och komposition innehallande foreningen |
| US4203912A (en) * | 1977-10-19 | 1980-05-20 | Johnson, Matthey & Co., Limited | Compositions containing platinum |
| US4234499A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Cis-diammireplatinum(II) organophosphate complexes |
| US4234500A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| US4291023A (en) * | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors using cis-diammineplatinum (II) organophosphate complexes |
| US4248840A (en) * | 1979-03-07 | 1981-02-03 | Engelhard Minerals And Chemicals Corporation | Cis-diammineplatinum(II) orthophosphate complexes |
| US4271085A (en) * | 1979-06-20 | 1981-06-02 | Engelhard Minerals & Chemicals Corporation | Cis-platinum (II) amine lactate complexes |
| US4322362A (en) * | 1980-07-28 | 1982-03-30 | Bristol-Myers Company | Salts of 2-hydroxymalonate platinum complexes |
-
1981
- 1981-01-23 JP JP56009463A patent/JPS57123198A/ja active Granted
-
1982
- 1982-01-07 DE DE8282200020T patent/DE3260164D1/de not_active Expired
- 1982-01-07 EP EP82200020A patent/EP0057023B1/en not_active Expired
- 1982-01-18 CA CA000394370A patent/CA1180009A/en not_active Expired
- 1982-01-20 GB GB8201616A patent/GB2091731B/en not_active Expired
- 1982-01-22 AU AU79765/82A patent/AU557336B2/en not_active Expired
-
1983
- 1983-04-14 US US06/485,584 patent/US4575550A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU7976582A (en) | 1982-07-29 |
| JPS637194B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-02-15 |
| DE3260164D1 (en) | 1984-06-28 |
| EP0057023B1 (en) | 1984-05-23 |
| EP0057023A1 (en) | 1982-08-04 |
| US4575550A (en) | 1986-03-11 |
| GB2091731B (en) | 1985-01-30 |
| GB2091731A (en) | 1982-08-04 |
| AU557336B2 (en) | 1986-12-18 |
| JPS57123198A (en) | 1982-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1180009A (en) | Platinum complexes | |
| Hay et al. | A convenient synthesis of the tetra-aza-macrocyclic ligands trans-[14]-diene, tet a, and tet b | |
| CA1258865A (en) | Platinum complexes | |
| EP0198051A1 (en) | Gadolinium chelates as nmr contrast agents | |
| Melby | Cysteine and cysteine ester complexes with molybdenum (V) and molybdenum (VI) | |
| CA1171425A (en) | Organic platinum complexes and uses | |
| CA1317937C (en) | Gadolinium chelates with carboxymethyl derivatives of polyazamacrocycles as nmr contrast agents | |
| JPH036156B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CA1227133A (en) | Platinum or palladium complexes | |
| AT394725B (de) | Verfahren zur herstellung von neuen mitomycin-c-analogen | |
| Jones et al. | The relative nephrotoxicity of cisplatin, cis-[Pt (NH3) 2 (guanosine) 2] 2+, and the hydrolysis product of cisplatin in the rat | |
| EP0282672B1 (en) | Novel platinum complexes | |
| Buckingham et al. | N-Terminal addition of glycine to amino acid and peptide esters activated by the cobalt (III) ion | |
| JP2008044882A (ja) | ５−アミノレブリン酸リン酸塩の新規結晶及びその製造方法 | |
| US4419351A (en) | Platinum-dioxopyrimidine complexes | |
| Boogaard et al. | 4-Methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anti-tumour activity | |
| Scarrow et al. | Ferric ion sequestering agents. 19. Synthesis of N-alkyl-3-hydroxy-2 (1H)-pyridinones and coordination complexes with iron (III) | |
| Lijinsky et al. | Relative carcinogenic effectiveness of derivatives of nitrosodiethylamine in rats | |
| JPS61171495A (ja) | 白金錯体類及びその製造方法 | |
| KR100314720B1 (ko) | 포스파젠 삼합체에 도입된 백금 착물, 그의 제조방법 및 그를 유효성분으로 하는 항암제 | |
| WO1984004922A1 (en) | Copper complex for treating cancer | |
| Maeda et al. | Synthesis of seleno-and thioguanine-platinum (II) complexes and their antitumor activity in mice | |
| JPH0358358B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69607217T2 (de) | Borverbindungen | |
| KR890004351B1 (ko) | 항 종양성 백금 착체의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |